194 related articles for article (PubMed ID: 20447380)
1. Superior serum half life of albumin tagged TNF ligands.
Müller N; Schneider B; Pfizenmaier K; Wajant H
Biochem Biophys Res Commun; 2010 Jun; 396(4):793-9. PubMed ID: 20447380
[TBL] [Abstract][Full Text] [Related]
2. Trimeric coiled-coil domain of human pulmonary surfactant protein D enhances zinc-binding ability and biologic activity of soluble TRAIL.
Wu X; Li P; Qian C; Li O; Zhou Y
Mol Immunol; 2009 Jul; 46(11-12):2381-8. PubMed ID: 19481806
[TBL] [Abstract][Full Text] [Related]
3. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
4. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
6. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs.
Zhan J; Chen Y; Yuan HY; Li H; Lu H
Biotechnol Lett; 2012 Mar; 34(3):417-23. PubMed ID: 22083716
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
9. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein.
Wu X; He Y; Falo LD; Hui KM; Huang L
Mol Ther; 2001 Mar; 3(3):368-74. PubMed ID: 11273779
[TBL] [Abstract][Full Text] [Related]
10. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
11. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
13. Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris.
Lei J; Guan B; Li B; Duan Z; Chen Y; Li H; Jin J
Protein Expr Purif; 2012 Jul; 84(1):154-60. PubMed ID: 22609631
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
15. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
17. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines.
Phillips TA; Ni J; Hunt JS
Placenta; 2001; 22(8-9):663-72. PubMed ID: 11597186
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
19. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L.
Berg D; Lehne M; Müller N; Siegmund D; Münkel S; Sebald W; Pfizenmaier K; Wajant H
Cell Death Differ; 2007 Dec; 14(12):2021-34. PubMed ID: 17703232
[TBL] [Abstract][Full Text] [Related]
20. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
